Insights & Publications


Understanding Clinician Perspective for a Successful Point-of-Care Urine Drug Screen Test Implementation

Understanding clinician perspective for a successful point-of-care urine drug screen test implementation Nov. 20, 2023 Alice Pedersen, MBA,BS MLS(ASCP) Photo 176460444 © Olga Ostapenko | Though it is known that point-of-care (POC) urine drug screening (UDS) has its limitations, clinicians request POC UDS due to its convenience and cost effectiveness. Common clinical recommendations are…

Read More

Applying Laboratory Quality Principles to Real World Point-of-Care Testing Systems

Kathleen David, MT (ASCP) Jeanne Mumford, MLS (ASCP)     For a printable version of the August CE Story and test go HERE or to take test online go HERE. For more information, visit the Continuing Education tab. LEARNING OBJECTIVES Upon completion of this article, the reader will be able to: 1. Discuss the need for a quality…

Read More

Utility of Commercially Available Quantitative hCG Immunoassays as Tumor Markers in Trophoblastic and Non-Trophoblastic Disease

Abstract Background: The use of quantitative human chorionic gonadotropin (hCG) as a tumor marker is widely accepted despite lack of FDA-approval for oncology. Differences in iso- and glycoform recognition among hCG immunoassays is well established, exhibiting wide inter-method variability. Here, we assess the utility of 5 quantitative hCG immunoassays for use as tumor markers in…

Read More

Why Labs Should Partner with Payers and Providers

Through these collaborations, clinical laboratories can use their expertise and data to improve outcomes, save money, and increase their influence within the healthcare system.

Read More

Laboratory Developed Tests: Regulation, Assay Development, and Impact on Patient Care

JMSACL_VALID_Intro Paragraph_FINAL     Journal of Mass Spectrometry and Advances in the Clinical Lab | Laboratory Developed Tests: Regulation, Assay Development, and Impact on Patient Care | by Elsevier

Read More